for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-AstraZeneca says US FDA grants Lynparza BTD for prostate cancer

Jan 28 (Reuters) - AstraZeneca Plc :

* Lynparza granted BTD in US for prostate cancer

* US FDA has granted breakthrough therapy designation (btd) for oral poly adp-ribose polymerase (parp) inhibitor Lynparza

* Decision to assign a BTD for Lynparza is based on results of toparp-a phase II trial

* Breakthrough therapy designation for Lynparza in this patient population means FDA will expedite review of submission data within 60 days of receipt Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up